National Comprehensive Cancer Network

About NCCN

NCCN Flash UpdatesTM: NEW and Updated NCCN Guidelines® Published

NCCN has published NEW NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) with NCCN Evidence Blocks™ for the following disease sites:

  • Chronic Myelogenous Leukemia, Version 1.2016
  • Multiple Myeloma, Version 2.2016


NCCN has published updates to the NCCN Guidelines® for Bone Cancer. These NCCN Guidelines are currently available as Version 1.2016.

  • Osteosarcoma
    • For adjuvant treatment, consider changing chemotherapy is now a category 2B. (OSTEO-2)
    • Radium 223 dichloride (Ra 223) is new to the page. (OSTEO-4)
  • Bone Cancer Systemic Therapy Agents
    • Sorafenib + everolimus added as an option for second-line therapy for relapsed/refractory or metastatic osteosarcoma. (BONE-B)

For the complete updated versions of the NCCN Guidelines, NCCN Guidelines with NCCN Evidence Blocks™,  NCCN Drug & Biologics Compendium (NCCN Compendium®), and NCCN Chemotherapy Order Templates (NCCN Templates®), please visit

To access the NCCN Biomarkers Compendium®, please visit

To view the NCCN Guidelines for Patients®, please visit

Free NCCN Guidelines apps iPhone, iPad, and Android devices are now available! Visit

 About NCCN Flash Updates™ 

NCCN Flash Updates™ is a subscription service from NCCN that provides timely notification of updated and new information appearing in the NCCN Guidelines, the NCCN Compendium®, and other NCCN Content. 

Subscribe to NCCN Flash Updates™ 


National Comprehensive Cancer Network® (NCCN®)

275 Commerce Drive, Suite 300

Fort Washington, PA 19034

Telephone: +1 215.690.0300 Fax: +1 215.690.0280 

Access information on permissions and licensing of NCCN Content  

© 2015 National Comprehensive Cancer Network. All Rights Reserved.